 |
市場調查報告書
商品編碼
1608740
硬皮症藥物市場：依藥物類別、類型、給藥途徑、分銷管道、地區Systemic Scleroderma Treatment Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
系統性硬皮症藥物市場預計 2024 年價值 17.1 億美元，預計 2031 年將達到 23.9 億美元，2024 年至 2031 年複合年成長率為 4.9%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 市場規模（2024年） | 17.1億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測期複合年成長率（2024-2031） | 4.90% | 預計金額（2031年） | 23.9億美元 |
系統性硬皮症是一種慢性自體免疫結締組織疾病，會導致皮膚和結締組織硬化和收緊。其特徵是身體細胞和組織中膠原蛋白過度生成，導致纖維化和疤痕。目前，系統性硬皮症尚無確定的治療方法，可用於控制症狀和減緩疾病進展的治療方法也有限。系統性硬皮症治療市場包括藥物、治療劑、醫療設備和其他用於治療疾病的產品。由於患病率上升和治療選擇有限，預計該市場在未來幾年將大幅成長。
市場動態：
全球系統性硬皮症治療市場是由全球系統性硬皮症發病率和盛行率不斷增加所推動的。據硬皮症基金會稱，美國約有 30 萬人，全世界有數百萬人患有硬皮症。然而，對該疾病發病機制的了解有限、缺乏治療選擇以及缺乏核准的全身性藥物，對市場成長構成了挑戰。然而，正在進行的新藥和治療方法研究有可能擴大治療領域。此外，到 2030 年，主要市場醫療保健成本的上升預計將推動市場擴張。
本報告的主要特點
本報告對全球系統性硬皮症治療藥物市場進行了詳細分析，並列出了以2023年為基準年的預測期（2024-2031年）的市場規模和複合年成長率。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球系統性硬皮症治療市場的主要企業進行了分析。
本報告涵蓋的主要企業包括：GSK plc、Certa Therapeutics、Aisa Pharma, Inc.、Corbus Pharmaceuticals、AbbVie, Inc.、Biogen、Novartis AG、AstraZeneca、Celgen Corporation、ONO PHARMACEUTICAL CO., LTD.、Teva Pharmaceutical .、勃林格殷格翰國際有限公司及MediciNova, Inc.
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球系統性硬皮症治療藥物市場報告針對該行業的各個相關人員相關者，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球硬皮症治療藥物市場的各種策略矩陣，將促進相關人員的決策。
目錄
第1章 分析目的與前提
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map (COM)
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特的分析
- 企業合併(M&A) 場景
- 流行病學
第4章系統性硬皮症藥物市場：依藥物類別，2019-2031（十億美元）
- 免疫抑制劑
- 磷酸二酯酶5抑制劑-PHA
- 內皮素受體拮抗劑
- 鈣離子通道阻斷劑
- 前列腺環素類似物
- 其他
第5章系統性硬皮症治療市場：依類型分類，2019-2031（十億美元）
- 局限性系統性硬皮症
- 瀰漫性系統性硬皮症
- 中線硬化
第6章 系統性硬皮症藥物市場：依給藥途徑分類，2019-2031 年（十億美元）
- 口服
- 胃腸外的
- 其他
第7章系統性硬皮症治療市場：依通路分類，2019-2031（十億美元）
- 醫院藥房
- 網路藥房
- 零售藥房
第8章全球系統性硬皮症藥物市場：按地區分類，2019-2031 年（十億美元）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第9章 競爭格局
- GSK plc
- Certa Therapeutics
- Aisa Pharma, Inc.
- Corbus Pharmaceuticals
- AbbVie, Inc.
- Biogen
- Novartis AG
- AstraZeneca
- Celgen Corporation
- ONO PHARMACEUTICAL CO., LTD.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH.
- MediciNova, Inc.
第10章分析師建議
- 《命運之輪》
- 分析師觀點
- Coherent Opportunity Map (COM)
第11章 參考文獻與調查方法
- 參考
- 分析方法
- 關於相干市場洞察
The systemic scleroderma treatment market is estimated to be valued at USD 1.71 Bn in 2024 and is expected to reach USD 2.39 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 1.71 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.90% | 2031 Value Projection: | 2.39 Bn |
Systemic scleroderma is a chronic autoimmune connective tissue disorder that causes hardening and tightening of the skin and connective tissues. It is characterized by the overproduction of collagen in the cells and tissues of the body leading to fibrosis or scarring. Currently, there is no cure for systemic scleroderma and the treatment options are limited to manage its symptoms and slow disease progression. The systemic scleroderma treatment market comprises drugs, therapies, medical devices and other products being used to treat this condition. With rising prevalence and limited treatment options, this market is poised to grow significantly in the coming years.
Market Dynamics:
The global systemic scleroderma treatment market is driven by the increasing incidence and prevalence of systemic scleroderma worldwide. According to Scleroderma Foundation, around 300,000 people in the U.S. and millions worldwide suffer from scleroderma. However, limited understanding of disease etiology, scarce treatment options, and lack of approved drugs for systemic forms pose challenges to market growth. Nonetheless, ongoing research on novel drugs and therapies holds promise to widen the treatment landscape. Furthermore, rising healthcare expenditures in major markets will facilitate market expansion through 2030.
Key Features of the Study:
This report provides in-depth analysis of the global systemic scleroderma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global systemic scleroderma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc, Certa Therapeutics, Aisa Pharma, Inc., Corbus Pharmaceuticals, AbbVie, Inc., Biogen, Novartis AG, AstraZeneca, Celgen Corporation, ONO PHARMACEUTICAL CO., LTD., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., and MediciNova, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global systemic scleroderma treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- Immunosuppressant
- Phosphodiesterase 5 inhibitors - PHA
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Prostacyclin Analogues
- Others
- Type Insights (Revenue, USD Bn, 2019 - 2031)
- Limited Systemic Sclerosis
- Diffused Systemic Sclerosis
- Sine Sclerosis
- Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Parenteral
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc
- Certa Therapeutics
- Aisa Pharma, Inc.
- Corbus Pharmaceuticals
- AbbVie, Inc.
- Biogen
- Novartis AG
- AstraZeneca
- Celgen Corporation
- ONO PHARMACEUTICAL CO., LTD.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH.
- MediciNova, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Systemic Scleroderma Treatment Market, By Drug Class
- Systemic Scleroderma Treatment Market, By Type
- Systemic Scleroderma Treatment Market, By Route of Administration
- Systemic Scleroderma Treatment Market, By Distribution Channel
- Systemic Scleroderma Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
4. Systemic Scleroderma Treatment Market, By Drug Class, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Immunosuppressant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Phosphodiesterase 5 inhibitors - PHA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Endothelin Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Prostacyclin Analogues
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Systemic Scleroderma Treatment Market, By Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Limited Systemic Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Diffused Systemic Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Sine Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Systemic Scleroderma Treatment Market, By Route of Administration, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Systemic Scleroderma Treatment Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Systemic Scleroderma Treatment Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Certa Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aisa Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Corbus Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgen Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ONO PHARMACEUTICAL CO., LTD.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MediciNova, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
